FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911759816> ?p ?o ?g. }

• W2911759816 endingPage "574" @default.
• W2911759816 startingPage "574" @default.
• W2911759816 abstract "574 Background: Epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) are approved in RAS WT mCRC; however, patients (pts) will develop resistance to these agents. Alterations in glutamine (Gln) metabolism play a critical role in cancer cell growth. In cancers such as CRC, EGFR and Gln cooperate to provide signals and fuel for mitogen activated protein kinase-dependent cell growth. Our in vitro data show that Gln abrogates EGFR inhibition, and blockade of Gln transport restores sensitivity. We also observed a greater antitumor response in vivo with EGFR mAb plus CB-839, an inhibitor of a rate-limiting enzyme of Gln metabolism, than either agent alone. We designed a phase I/II study (NCT03263429) to evaluate CB-839 + panitumumab + irinotecan in anti-EGFR refractory RAS WT mCRC. Methods: Dose escalation used a Bayesian continual reassessment method targeting a 25% toxicity probability. CB-839 (600 mg or 800 mg twice daily [BID]) were evaluated with panitumumab (6 mg/kg) and irinotecan (180 mg/m 2 ). Irinotecan was included in phase I to establish a future phase II dose of the triplet. Prior EGFR mAb treatment (tx) was not required for phase I. Dose-limiting toxicity (DLT) was any tx-related non-hematologic ≥Gr 3 toxicity (except fatigue, rash, or elevated liver enzymes) or ≥Gr 4 hematologic toxicity during the first 28 days. Results: Nine pts have been enrolled; 2 were not evaluable for DLT and replaced. Zero DLTs were observed at dose level 1 (n = 3) or 2 (n = 4); 2 more pts are needed to confirm the maximum tolerated dose (MTD). Most frequent toxicities were anemia and hypomagnesemia (88%) and elevated alkaline phosphatase, nausea, and rash (75%), most ≤Gr 2. One of 7 evaluable pts (14%) has an ongoing partial response, and 5 pts had stable disease (SD; 71%). Three pts have been on tx > 6 months, and 3 pts with prior EGFR mAb tx achieved SD. Conclusions: Triplet combination was tolerable at full doses of each drug, and preliminary antitumor activity was observed in a majority of pts. Phase II will begin after phase I completion and will evaluate efficacy of CB-839 (800 mg BID) and panitumumab (6 mg/kg). Imaging studies using investigational PET tracers to evaluate Gln metabolism as a function of tumor response are planned. Clinical trial information: NCT03263429." @default.
• W2911759816 created "2019-02-21" @default.
• W2911759816 creator A5010469485 @default.
• W2911759816 creator A5013233073 @default.
• W2911759816 creator A5013695327 @default.
• W2911759816 creator A5013905850 @default.
• W2911759816 creator A5028063270 @default.
• W2911759816 creator A5039492614 @default.
• W2911759816 creator A5043300006 @default.
• W2911759816 creator A5046249010 @default.
• W2911759816 creator A5046643485 @default.
• W2911759816 creator A5047170855 @default.
• W2911759816 creator A5066217699 @default.
• W2911759816 creator A5075392197 @default.
• W2911759816 creator A5082299645 @default.
• W2911759816 creator A5088976086 @default.
• W2911759816 date "2019-02-01" @default.
• W2911759816 modified "2023-10-16" @default.
• W2911759816 title "CB-839, panitumumab, and irinotecan in RAS wildtype (WT) metastatic colorectal cancer (mCRC): Phase I results." @default.
• W2911759816 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.574" @default.
• W2911759816 hasPublicationYear "2019" @default.
• W2911759816 type Work @default.
• W2911759816 sameAs 2911759816 @default.
• W2911759816 citedByCount "4" @default.
• W2911759816 countsByYear W29117598162020 @default.
• W2911759816 countsByYear W29117598162021 @default.
• W2911759816 countsByYear W29117598162023 @default.
• W2911759816 crossrefType "journal-article" @default.
• W2911759816 hasAuthorship W2911759816A5010469485 @default.
• W2911759816 hasAuthorship W2911759816A5013233073 @default.
• W2911759816 hasAuthorship W2911759816A5013695327 @default.
• W2911759816 hasAuthorship W2911759816A5013905850 @default.
• W2911759816 hasAuthorship W2911759816A5028063270 @default.
• W2911759816 hasAuthorship W2911759816A5039492614 @default.
• W2911759816 hasAuthorship W2911759816A5043300006 @default.
• W2911759816 hasAuthorship W2911759816A5046249010 @default.
• W2911759816 hasAuthorship W2911759816A5046643485 @default.
• W2911759816 hasAuthorship W2911759816A5047170855 @default.
• W2911759816 hasAuthorship W2911759816A5066217699 @default.
• W2911759816 hasAuthorship W2911759816A5075392197 @default.
• W2911759816 hasAuthorship W2911759816A5082299645 @default.
• W2911759816 hasAuthorship W2911759816A5088976086 @default.
• W2911759816 hasConcept C121608353 @default.
• W2911759816 hasConcept C126322002 @default.
• W2911759816 hasConcept C143998085 @default.
• W2911759816 hasConcept C178790620 @default.
• W2911759816 hasConcept C185592680 @default.
• W2911759816 hasConcept C2777506169 @default.
• W2911759816 hasConcept C2778332735 @default.
• W2911759816 hasConcept C2778570526 @default.
• W2911759816 hasConcept C2779438470 @default.
• W2911759816 hasConcept C2779682216 @default.
• W2911759816 hasConcept C2779998722 @default.
• W2911759816 hasConcept C2780259306 @default.
• W2911759816 hasConcept C29730261 @default.
• W2911759816 hasConcept C502942594 @default.
• W2911759816 hasConcept C526805850 @default.
• W2911759816 hasConcept C71924100 @default.
• W2911759816 hasConcept C98274493 @default.
• W2911759816 hasConceptScore W2911759816C121608353 @default.
• W2911759816 hasConceptScore W2911759816C126322002 @default.
• W2911759816 hasConceptScore W2911759816C143998085 @default.
• W2911759816 hasConceptScore W2911759816C178790620 @default.
• W2911759816 hasConceptScore W2911759816C185592680 @default.
• W2911759816 hasConceptScore W2911759816C2777506169 @default.
• W2911759816 hasConceptScore W2911759816C2778332735 @default.
• W2911759816 hasConceptScore W2911759816C2778570526 @default.
• W2911759816 hasConceptScore W2911759816C2779438470 @default.
• W2911759816 hasConceptScore W2911759816C2779682216 @default.
• W2911759816 hasConceptScore W2911759816C2779998722 @default.
• W2911759816 hasConceptScore W2911759816C2780259306 @default.
• W2911759816 hasConceptScore W2911759816C29730261 @default.
• W2911759816 hasConceptScore W2911759816C502942594 @default.
• W2911759816 hasConceptScore W2911759816C526805850 @default.
• W2911759816 hasConceptScore W2911759816C71924100 @default.
• W2911759816 hasConceptScore W2911759816C98274493 @default.
• W2911759816 hasIssue "4_suppl" @default.
• W2911759816 hasLocation W29117598161 @default.
• W2911759816 hasOpenAccess W2911759816 @default.
• W2911759816 hasPrimaryLocation W29117598161 @default.
• W2911759816 hasRelatedWork W1571296368 @default.
• W2911759816 hasRelatedWork W1997977112 @default.
• W2911759816 hasRelatedWork W2006928910 @default.
• W2911759816 hasRelatedWork W2017982166 @default.
• W2911759816 hasRelatedWork W2064588703 @default.
• W2911759816 hasRelatedWork W2162227144 @default.
• W2911759816 hasRelatedWork W2410581778 @default.
• W2911759816 hasRelatedWork W2597010356 @default.
• W2911759816 hasRelatedWork W2697321689 @default.
• W2911759816 hasRelatedWork W4246981307 @default.
• W2911759816 hasVolume "37" @default.
• W2911759816 isParatext "false" @default.
• W2911759816 isRetracted "false" @default.
• W2911759816 magId "2911759816" @default.
• W2911759816 workType "article" @default.